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Gallic acid (GA) is a bioactive phytoconstituent that has been reported to prevent a number of 2 
diseases. However, there is no systematic review to-date on its anti-diabetic and cardioprotective 3 
potential including molecular mechanisms for such activities. This review aims to summarize the 4 
anti-diabetic and cardioprotective effects of gallic acid and further propose a molecular 5 
mechanism of its anti-diabetic effects. Accumulation of associated literature was conducted 6 
through the use of databases including Google Scholar, Pubmed, Web of Science, Science Direct 7 
and Scopus databases. Articles published until December 2018 were extracted and all the 8 
retracted articles were sorted based on the inclusion and exclusion criteria and relevant articles 9 
were further consulted for necessary information. We have found substantial investigations in 10 
animals and cultured cells that supports anti-diabetic and cardioprotective effects of GA with 11 
several underlying mechanisms including antioxidant enzyme systems and non-enzymatic 12 
defense mechanisms. The reported antioxidant activity of GA as well as the modulation of some 13 
key proteins linked to diabetes could be a part of the mechanisms by which GA showed anti-14 
diabetic effect. In summary, it is evident that GA is one of the promising dietary phytochemicals 15 
that could be beneficial for the treatment and management of diabetes and associated myocardial 16 
damage. 17 
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Diabetes mellitus (DM) and cardiovascular diseases (CVDs) are the two most common causes of 2 
deaths that are spreading spontaneously around the world.[1, 2] Approximately 347 million people 3 
around the world are suffering from DM[3] and it is projected that about 592 million people 4 
worldwide will have DM by 2035.[4] In diabetes, glucose utilization is reduced as a results of 5 
compromised insulin secretion.[5] DM causes different ailments including neuropathy, micro and 6 
macro vascular diseases as well as nephropathy through inhibiting body’s antioxidant 7 
mechanisms.[6] A number of reports confirmed that the link between DM and CVDs was the 8 
most predominant cause of morbidity and mortality in diabetic patients.[4] According to various 9 
studies, hyperglycemia is a prime cause of CVDs in DM patients.[7] Excessive blood glucose in 10 
DM patients can react with amino acid residues of proteins as well as free amino acids to form 11 
advanced glycation end products (AGEs) by non-enzymatic glycosylation reaction and this plays 12 
an important role in the pathogenesis of diabetic complications including cardiomyopathy.[8] The 13 
high levels of circulating and myocardial AGEs remains elevated [9] in DM which also 14 
contributes to heart failure.[10] Diabetes increases atherosclerotic progression and adversely 15 
contributes to the lipid profile resulting in the increased risk of myocardial infraction (MI) .[11] A 16 
number of molecules are currently exists to control DM and CVDs with varying degrees of 17 
success, but there is still no magic molecule that can control DM and its associated CVDs 18 
simultaneously. 19 
Gallic acid (GA), chemically known as 3,4,5-trihydroxybenzoic acid, is a naturally 20 
occurring aromatic polyphenolic acid mostly found in different fruits and other plants.[12] GA 21 
mainly occurs in plants in the form of free acids or as esters in catechin derivatives and 22 
hydrolysable tannins (Fig. 1). Different fruits and foodstuffs contain different amounts of GA 23 
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including strawberries, bananas, grapes[13, 14], teas[15], cloves[16], and vinegars[17]. GA has been 1 
reported to occur in a number of terrestrial plants such as Cynomorium coccineum, Garcinia 2 
densivenia, Bridelia micrantha, Diospyros cinnabarina, Terminalia bellerica[18, 19],  as well as in 3 
aquatic plant Myriophyllum spicatum, and the blue-green algae Microcystis aeruginosa.[20] 4 
Various oak species[21], stem bark of Boswellia dalzielii[22], and Caesalpinia mimosoides[23], also 5 
contain GA. GA has been reported to be used as a dietary herbal supplement[24] and about thirty 6 
ayurvedic formulations containing considerable amount of GA are used for different diseases in 7 
India.[25] GA is a strong natural antioxidant and has the ability to combat different reactive 8 
oxygen species (ROS).[26] GA is reported to affect multiple pharmacological and biochemical 9 
pathways through which it exerts a number of biological activities including anti-inflammatory, 10 
anti-diabetic, cardioprotective, anti-cancer and hepatoprotective activity (Table 1). However, 11 
there is no systematic review to-date covering its anti-diabetic and cardioprotective effects. The 12 
aim of this review is to summarize the anti-diabetic and cardioprotective effects of GA with 13 
focus on underlying mechanisms of action that is available in published literature using afore-14 
mentioned databases.  15 
Search strategy 16 
A comprehensive literature search was conducted by using several databases including PubMed, 17 
Google Scholar, Web of Science, Science Direct and Scopus with the term ‘gallic acid’ with 18 
‘anti-diabetic’, ‘diabetes’, ‘cardioprotective’, ‘cardiovascular disease’ ‘myocardial damage’ and 19 
‘cardiotoxicity’. Reports that are only in English were selected due to the language barrier, time 20 
efficiency and non-feasible costs of translation. 21 
Selection of studies for inclusion in the systematic review 22 
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To prepare this review, a number of criteria have been structured to include articles in this 1 
review. The following types of reports were included in this review: a) in vivo animal studies, b) 2 
in vitro studies, c) studies that include the effects of GA on diabetes and cardiovascular diseases, 3 
e) studies that indicate the concentrations or doses employed and the form of administration and 4 
f) studies that pointed out the mechanisms of action of GA. 5 
Data extraction 6 
All the searched literature were assessed for the information according to surname of first author, 7 
year of publication, GA, test system, observation, result, concentrations tested and suggested 8 
molecular mechanism involved. The general steps of the data search, the exclusion-inclusion 9 
data and other relevant information are presented in Fig. 2. 10 
Literature review 11 
A total number of 2217 reports were revealed under anti-diabetic and cardioprotective effects of 12 
GA using different databases including PubMed, Google Scholar, Web of Science, Science 13 
Direct and Scopus in which 35 studies met the inclusion criteria. The exclusion of 2182 14 
documents was because of duplication of information, absence of any title and non-relevance of 15 
the study.  16 
Anti-diabetic effect of GA 17 
DM is a chronic metabolic disorder characterized by hyperglycemia as a results of reduction 18 
of secretion and action of insulin.[26] A number of complications are directly linked with DM 19 
including neuropathy, cardiovascular (micro and macro vascular) diseases and nephropathy 20 
through affecting body’s antioxidant mechanisms.[6] A number of reports confirmed that the 21 
excessive production of ROS and oxidative stress plays an essential role in the progression of 22 
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diabetes and its complications through alteration of lipid peroxide production, antioxidant 1 
enzyme levels, auto-oxidation of glucose, glutathione metabolism, formation of AGEs as well as 2 
alteration of several signaling pathways in different tissues.[27, 28] A number of phytomedicines 3 
and herbal preparations have long been evaluated to develop natural product based new anti-4 
diabetic drug. GA is a natural dietary triphenolic antioxidant that  has diverse bioactivity 5 
including radical scavenging activity, inhibition of lipid peroxidation (LPO), metal ion chelation, 6 
maintenance of endogenous defence system and interfering cell signaling pathways.[29] Literature 7 
study demonstrated that GA has the ability to decrease the harmful consequences in diabetic rats 8 
via altering biochemical and histopathological biomarkers of oxidative stress as well as affecting 9 
a number of cellular signaling pathways. It also showed protection of pancreatic β-cell, increased 10 
cellular glucose uptake as well as increase plasma insulin secretion and insulin sensitivity (Table 11 
2). Table 2 and 4 summarized the anti-diabetic effect of GA in both in-vivo and in-vitro test 12 
models. A number of possible mechanisms for anti-diabetic effect of GA is shown in Fig. 3.  13 
In vivo experiments of GA revealed that GA has the ability to alter different biochemical 14 
parameters in diabetic animals. A number of reports demonstrated that treatment of GA at a dose 15 
of 10-20 mg/kg b.w. in steptozotocin (STZ) induced diabetic rats can reduce blood glucose level, 16 
total cholesterol (TC), triglyceride (TG), uric acid (UA) and serum creatinine (SC), while 17 
increasing plasma insulin (PI), C-peptide and glucose tolerance level.[30, 31] In 2014, Kade, et al., 18 
showed that GA mitigates pancreatic dysfunction by its anti-oxidative effect (increased vit C, 19 
glutathione, Fe2+ chelation and Fe3+ reduction ability of pancreas) and  enhances glucose uptake 20 
in STZ-induced oxidative stressed rat.[32] Another report by Ramkumar, et al., (2014) showed 21 
protective effect of GA on alloxan-induced oxidative stressed diabetic rats via scavenging of 22 
ROS, upregulation of antioxidant enzymes (catalase (CAT), suproxide dismutase (SOD), 23 
8 
 
glutathione peroxides (GPx)) and increased insulin secretion.[33] Other report by Al-Salih et 1 
al.(2010) showed synergistic effect of GA with tannic acid that decreased blood glucose level 2 
and serum malondialdehyde (MDA) level in alloxan induced female diabetic rabbits and in-vitro 3 
rat pancreas homogenate.[34, 35] It is reported that MDA is the accumulated ROS induced 4 
oxidative breakdown product of phospholipid which has key role in modifying low density 5 
lipoprotein (LDL), non-enzymatic and auto-oxidative glycosylation as well as act as a surrogate 6 
marker of oxidative stress in diabetics.[36]  7 
Peroxisome proliferator-activated receptors- alpha, beta, gamma (PPAR-α, β, γ) are nuclear 8 
receptor proteins that play an essential role in the regulation of glucose and fat metabolism.[37] A 9 
number of anti-diabetic drugs such as thiazolidinediones (TZDs) exert their action (increased 10 
insulin sensitivity) via interacting with PPAR-γ.[38] PGC1α is another protein that interact with 11 
PPAR-γ to control a number of transcription factors which helps to regulate mitochondrial 12 
biogenesis, oxidative metabolism as well as inhibits pro-inflammatory cytokine production.[39-42] 13 
AMP-activated protein kinase (AMPK) has a key role in cellular glucose and fatty acid uptake 14 
via translocation of GLUT4 in the plasma membrane[41, 43, 44] and inducing mitochondrial 15 
biogenesis by regulating peroxisome proliferator-activated receptor gamma coactivator 1-alpha 16 
(PGC1α).[45] AMPK also facilitate cellular fatty acid oxidation via upregulation and activation of 17 
PPAR-α, PGC1α and UCP.[46, 47] Mitochondrial uncoupling proteins (UCP2) help to control of 18 
mitochondria-derived ROS production.[48-50] Studies have shown that one of the mechanisms of 19 
AMPK action in maintaining intracellular redox regulation is to up-regulate the expression of 20 
mitochondrial UCP2 and SOD.[51, 52] Therefore, these proteins play a crucial role in glucose and 21 
fat metabolism as well as reducing cellular oxidative stress. Any molecules that interact with 22 
these key proteins could be important in the prevention and management of DM. Interestingly, a 23 
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number of reports studied and found that GA has the ability to alter a number of such cellular 1 
signaling pathways to exhibit its anti-diabetic action. A number of in vivo experiments 2 
demonstrated anti-diabetic effect of GA through the increase in glucose uptake, insulin 3 
sensitivity, adipocytokines as well as reduction in adipocyte hypertrophy caused by the 4 
upregulation of cellular PPAR-γ expression and translocation of GLUT4 in Akt signaling 5 
pathway in high fat diet induced hyperglycemic mice and rat.[53-55] Another interesting report 6 
showed that GA plays an important role in glucose and insulin homeostasis as well as 7 
thermogenesis through the activation of AMPK and by regulating mitochondrial function via the 8 
activation of PGC1α as well as elevation of UCP2 together with other genes related to energy 9 
expenditure in the brown adipose tissue.[56] Several in vitro experimental studies done in cultured 10 
cell lines and pancreatic cell homogenate (3T3-L1, RINm5F, isolated rat pancreas) showed that 11 
GA has the ability to induce GLUT4 translocation and glucose uptake activity, inhibit α-amylase 12 
and α-glucosidase, increases insulin secretion and prevent insulin amyloid fibril formation in the 13 
cultured cell lines which were further supported by in vivo studies reported elsewhere.[35, 57-59]  14 
From the above literature study, it is clear that GA exerts anti-diabetic effects not only by its 15 
antioxidant mechanism but also by inducing PPARγ and PGC1α expression, activating AMPK 16 
and Akt signaling pathway as well as enhancing glucose uptake through translocation and 17 
activation of GLUT4. GA further prevents mitochondrial dysfunction through upregulation of 18 
UCP proteins which leads to improve oxidative stress along with improved glucose metabolism 19 
and insulin resistance and ultimately showing anti-diabetic effect (Fig. 3). 20 
Cardioprotective effect of GA 21 
CVDs such as coronary artery disease, hypertensive heart diseases, and stroke are 22 
attributed for most of the mortalities around the world.[60] It is well established that DM increases 23 
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the incidence of CVDs and  a major risk factor for the development of CVDs.[61-63] Clinical 1 
studies showed that patients with type II DM possesses a number of risk factors for the 2 
development of CVDs including hyperglycemia, abnormalities of inflammatory mediators, lipid 3 
profiles and thrombolytic parameters, as well as other abnormalities associated with insulin 4 
resistance.[61] A significant number of studies over the last few decades confirmed that oxidative 5 
stress-related factor such as ROS, play an important role in the pathophysiology of CVDs and 6 
DM.[60, 64]  Clinical studies also demonstrated that antioxidant balance is a key indicator for 7 
diabetes induced myocardial damage and patients with diabetes and myocardial infraction (D-8 
MI) exhibit high level of total cholesterol (TC), triglyerides (TG), low-densitylipoprotein (LDL), 9 
cardiac markers such as creatine phosphokinase (CPK), creatine kinase-MB (CK-MB), aspartate 10 
aminotransferase (AST), C-reactive protein (CRP), lactate dehydrogenase (LDH), troponin-I 11 
(TnI) as well as low level of oxidative stress marker  such as high-density lipoprotein (HDL), 12 
superoxide dismutase (SOD), glutathione (GSH), malondialdehyde (MDA), catalase (CAT) in 13 
comparison to non-myocardial infraction (N-MI) patients.[65, 66] Therefore, antioxidant based 14 
interventions are an important tool to treat diabetes and associated CVDs. Natural polyphenols 15 
are one of the prominent antioxidants that has been reported to manage efficiently CVDs and 16 
DM.[67, 68]  17 
GA is a bioactive natural polyphenolic acid and possesses strong antioxidant activity. 18 
Over the last decade, a number of significant studies have been conducted on the health 19 
beneficial effects of GA including its cardioprotective and anti-diabetic activities. Table 3 and 4 20 
summarizes the cardioprotective effects of GA done in in-vivo or in-vitro test models. Elevation 21 
of lipid peroxidation in experimental myocardial infarction is an established phenomenon caused 22 
by oxidative modification of lipids by ROS as a results of cell damage and alterations in the 23 
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function of membrane proteins including ion channels, enzymes and receptors as well as 1 
produced pro-antherogenic and pro-inflammatory mediated toxic products.[69, 70] Clinically, CK, 2 
CK-MB, LDH, AST and ALT are found in the cardiac tissues that played different functions and 3 
act as a biomarker for damage of cardiac tissues by ROS and LPO such as in myocardial 4 
infarction whereas CRP and MDA are the products of inflammation and lipid peroxidation which 5 
act as a marker of oxidative stress.[71-73]  SOD, GPx, CAT are the first line defence antioxidants 6 
that play an indispensable role in the protective effect of cells against ROS and lipid 7 
peroxidation.[74] Literature study revealed that GA showed cardioprotective effect through 8 
improving antioxidant defence mechanisms via upregulation of enzymatic (CAT, SOD, GPx, 9 
glutathione reductase (GR) and glutathione-S-transferase (GST)) and non-enzymatic (GSH, Vit. 10 
C and E) antioxidants, reduction of LPO i.e. attenuates levels of TG, TC, LDL, very low density 11 
lipoprotein (VLDL) and MDA as well as downregulation of the activity of cardiac biomarkers 12 
(CK, CK-MB, AST, alanine transaminase (ALT), LDH, CRP and TnI) either in isoproterenol 13 
(ISO), STZ, doxorubicin (DOX), alumina (Al2O3), AGEs, cobalt chloride (CoCl2), diazinon, 14 
sodium fluoride (NaF), isoprenaline or cyclophosphamide (CYP)-induced cardiotoxicity in rat 15 
model.[75-85] DM increases the incident of CVDs development and interestingly GA showed 16 
cardioprotective effect through inhibition of LPO and boosting antioxidant defence mechanisms 17 
in STZ or alloxan-induced diabetic rat model.[76, 86] GA showed cardioprotective effect when 18 
given orally in different doses (15-120 mg/kg/daily b.w for 1-4 weeks) to experimentally induced 19 
myocardial infarcted rats.[75-85] Badavi, M., et al. (2014) and Ramezani-Aliakbari, et al. (2017) 20 
also found the attenuation of antioxidant defence mechanisms by different doses of GA in 21 
ischemic reperfusion in isolated rat heart tissue.[86, 87]  22 
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Lysosomal enzymes such as β-glucuronidase, β-N-acetylglucosaminidase, β-1 
galactosidase, also play important roles in the normal turnover of tissue proteins and other 2 
macromolecules. These enzymes are also  responsible for alterations in the rate of degradation of 3 
many tissue components such as abnormal release and activation of lysosomal enzymes during 4 
ischemia.[88]  Along with improving antioxidant defence mechanisms and reduction of LPO, GA 5 
has been reported to improve myocardial infraction via downregulation of liposomal enzymes in 6 
ISO-treated myocardial infarcted rats.[89] It is reported that the gap junction protein Connexin 43 7 
(Cx43) can express in connective tissues, inflammatory cells and vascular elements that help to 8 
reduces ventricular tachycardia (VT) incidence following myocardial infraction.[90] Na+/K+ 9 
ATPase (Sodium-potassium adenosine triphosphatase) is another enzyme found in all cell 10 
membrane that helps to maintain resting potential, transport, cell volume as well as signal 11 
transduction to regulate mitogen-activated protein kinases (MAPKs)  and ROS pathway.[91] In 12 
myocardial tissues, there is a correlation between decrease in heart function and decreased 13 
concentration of Na+/K+ ATPase.[92] El-Hussainy et al., (2016) and Padma et al., (2012) showed 14 
that GA has the ability to protect myocardial injury via upregulation of Cx43 and Na+/K+ 15 
ATPase in alumina or lindane induced myocardial injury in rats.[78, 93] Furthermore, cellular 16 
MAPKs signaling pathway is responsible to control a vast array of physiological processes. MAP 17 
kinase family such as c-Jun N-terminal kinases (JNKs), extracellular signal–regulated kinases 18 
(ERKs), p38 play key role to regulated MAPKs pathway by activating one another and help to 19 
control cell division (by ERKs)  or transcription (by JNKs).[94] Inflammatory cytokines, growth 20 
factors, oxidative stress by ROS, protein synthesis inhibitors, and other stress stimuli can activate 21 
MAPKs family.[95]  Activation of MAPKs  system through oxidative stress (excess ROS) has 22 
key role for the formation of AGEs that takes part in pathogenesis of myocardial toxicity and 23 
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accelerate atherosclerosis in DM.[96-98] AGEs also induce myocardial fibrosis through activation 1 
of extracellular matrix protein (ECR) such as collagen.[99] Smads (or SMADs) are another 2 
protein family that are the main signal transducers for receptors of transforming growth factor 3 
beta (TGF-β) and downregulation of TGF-β/Smads can induce accumulation of extracellular 4 
matrix (ECM) proteins such as collagen and promote cellular fibrosis.[100] Interestingly, literature 5 
study demonstrated that GA can prevent ISO-induced cardiac hypertrophy and fibrosis by 6 
improved oxidative stress and inhibition of collagen deposition via down regulation of JNK2, 7 
ERK signaling pathway and Smad3 binding activity in GA treated mice.[101] Later, Jin et al., 8 
(2017) confirmed that GA can attenuate cardiac remodeling and fibrosis in N-nitro-L-arginine 9 
methyl ester (L-NAME)-induced hypertensive mice through downregulation of  ECM such as 10 
collagen type I, collagen type III, and connective tissue growth factor (CTGF).[102] However, 11 
Akinrinde, et al., (2016) reproted that the protective effects of GA against CoCl2 -induced 12 
cardiorenal dysfunction via suppression of oxidative stress and activation of the ERK signaling 13 
pathway.[80]  Recent study by Jin, et al. (2017) reported that GA attenuates hypertension and 14 
cardiac hypertrophy in both in-vitro and in vivo test models.[102, 103] In vitro cardioprotective 15 
studies of GA were mainly conducted (10-100 µM) in cultured rat neonatal cardiomyocytes 16 
H9c2(2-1) cells treated by different agents such as AGE, L-NAME, ISO and renin-angiotensin II 17 
(Table 4). In vitro data also demonstrated that GA has the ability to reduce cardiotoxicity through 18 
inhibition of cell proliferation, elevation of cellular antioxidant mechanisms, inhibition of LPO 19 
and downregulation of JNK, Samds and GATA4-induced NADPH oxidase (Nox) signaling 20 
pathway following reduction of AGE-induced cytokines (tumor necrosis factor-alpha (TNF-α), 21 
TGF-β, inducible nitric oxide synthase (iNOS)) and matrix proteins, receptor for AGE (RAGE), 22 
tissue inhibitor metalloproteinase (TIMPs), matrix metalloproteinase (MMP)) of cultured 23 
14 
 
cells.[101-105] The in vitro results also support the in vivo cardioprotective data as mentioned in 1 
proposed mechanism of action of GA in fig. 3. 2 
 3 
Conclusion 4 
GA is a very common dietary plant constituent possessing strong antioxidant proprieties and 5 
used in several herbal formulations to treat different diseases. In this review, we have 6 
summarized the anti-diabetic and cardioprotective reports of GA published to-date. Studies done 7 
in in vivo and in vitro test models clearly demonstrated anti-diabetic and cardioprotective 8 
potential of GA. Such activities of GA were exerted through improving cellular antioxidant 9 
defence mechanisms, inhibiting lipid peroxidation as well as regulation of different key proteins 10 
related to DM and CVDs. A number of interesting studies were also found where GA showed 11 
significant protection against diabetes and diabetes induced myocardial damage. To conclude, 12 
the antioxidants based interventions as well as upregulation of key proteins was the major 13 
pathway for anti-diabetic activity of GA. Therefore, it is evident that GA can be considered as 14 
promising dietary lead molecule for the prevention of diabetes. The anti-diabetic studies on GA 15 
conducted over the last few years were mainly in vivo or in vitro models and data-related 16 
preclinical or clinical trials for such activities still remains absent. Thus, more clinical and 17 
pharmacokinetic investigation on GA is important to conclude on the anti-diabetic and 18 
cardioprotective potential of GA.  19 
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Table 1: Chemical name, molecular formula, chemical group and reported pharmacological 1 
activity of GA 2 





































Table 2: In vivo anti-diabetic activity of GA with its test model, dose used, route of 1 
administration and possible mechanism of action.  2 
Test model Dose/b.w Route of 
administration 
Mechanism of action Reference 
STZ-induced 
diabetic rat 
20 mg/kg for 
28 days 
Orally Reduction of serum TC, TG, LDL-
C, urea, UA, creatinine and 
increased plasma insulin, C-peptide 




10 and 20 for 
21 days 
Orally Reduction of blood glucose and 






for 21 days 
Intravenously Reduction of blood glucose and 
serum MDA levels. 
[34] 
STZ-induced 
oxidative stress in 
diabetic rat 
25 mg/kg for 
35 days 
Orally Significant increase ofpancreatic 
vitamin C and glutathione level and 
improvedROS scavenging, Fe2+ 
chelation and Fe3+ reduction 
property of the pancreas  
[32] 
Alloxan-induced 
oxidative stress in 
diabetic rat 
5, 10, and 20 
mg/kg for 45 
days 
Orally Reduction of blood glucose, 
increase insulin level, and 
upregulation of antioxidant 





10 mg/kg for 
14 days 
Intraperitoneally Reduction of blood glucose, TG, 
adipocyte size and upregulation of 
PPARγ expression and activation of 






20 mg/kg for 
30 days 
Orally Enhancing glucose uptake through 
translocation and activation of 





20 mg/kg for 
42 days  
Orally Reduction of TNF-α level and 
enhance upregulation of PPARγ 





10 mg/kg for 
28 days 
Intraperitoneally  Activation of AMPK and regulates 
mitochondrial function via the 






Table 3: In vivo cardioprotective activity of GA with its test model, dose used, route of 1 
administration and possible mechanism of action 2 
Test model Dose/b.w Route of 
administration 
Mechanism of action Reference 
ISO-induced 
myocardial 





Orally Reduction of LPO and myocardial 
infraction biomarker (↓CK, CK-MB, 
AST, alanine transaminase (ALT), LDH 
and troponin-T) as well as upregulation of 
enzymatic (↑SOD, CAT, GPx, GR and 
GST) and non-enzymic antioxidants 









Orally Reduction of serum glucose and LPO 
(↓TG, TC, LDL-C, VLDL-C) as well as 
increased dose dependently antioxidant 





15 mg and 
30 mg/kg 
Orally Reduction of LPO (↓CK-MB, MDA, TG, 
TC, LDL in serum) as well as increased 
non-enzymic antioxidant (GSH) and 










Reduction of LPO (↓CPK, CK-MB, TG, 
TC, LDL and LDH in serum)and  
increased antioxidant enzymes (↑GR, 
CAT and SOD) as well as upregulation of 









Orally Reduction of LPO (↓CK-MB, LDH, 
thiobarbituric acid reactive substances 
(TBARS), lipid hydroperoxides (LOOH)) 
and reduction of activity of lysosomal 
enzymes (↓β-glucuronidase, β-N-
acetylglucosaminidase, β-galactosidase, 
cathepsin-B and D) as well as increased 
non-enzymic antioxidant (GSH) in the 








Orally Reduction of serum cardiac marker 
enzymes, LPO, and membrane-bound 
Ca2+ ATPase, with a concomitant 




days (GSH) and enzymic antioxidants (↑SOD, 
CAT, GPx, and GST) as well as 









Orally Reduction of LPO (↓ MDA, LDH)and 
increased antioxidant enzymes (↑CAT, 








for 8  
weeks 
Orally  Reduction of LPO (↓ CK-MB, troponin I, 
LDH)and increased antioxidant enzymes 
(↑ CAT, SOD, GPx) in diabetic heart 
tissue. It also improved both left 
ventricular dysfunction and hypertrophy 








Orally Reduction of LPO (↓CK, LDH) and 
protein carbonyls (PCO)in plasmaand 
increased non-enzymic antioxidant (GSH) 
and enzymatic antioxidants (↑ SOD, 









Intraperitoneally Downregulation of atrial natriuretic 
peptide (ANP), brain natriuretic peptide 
(BNP), and beta-myosin heavy chain 
(MHC-β) as well as prevention of 
interstitial collagen deposition and 
expression of fibrosis-associated genes in 
cardiac tissues. Overall, prevention of 
cardiac hypertrophy and fibrosis through 









Orally  Reduction of oxidative stress (↓ serum 
CK-MB, LDH, AST, xanthine oxidase 
(XO), urea, MDA, creatinine, H2O2, NO,  










Orally  Reverses the oxidative stress markers (↓ 
MDA, H2O2, NO,  and ↑ GSH, SOD, 
CAT, GST) and increased antioxidant 
defense system as well as and reduces 




oxidative stress in 
rat's heart 
10 and 20 
mg/kg for 
7 days 
Intraperitoneally Reduction of LPO (↓TBARS, MDA) and 
increased non-enzymic antioxidant (GSH) 












Orally Reduction of cardiac marker enzymes 
activity (AST, ALT, CK and LDH), LPO 
(MDA) and elevated antioxidant 




dysfunction in rat 
60 and 
120 mg/kg 
for 7 days 
Intraperitoneally Reduction of LPO (↓MDA, H2O2) and 
restores the enzymic (↑SOD, GPx, CAT, 
GST) and non-enzymic (↑GSH) 
antioxidants and also attenuates 











Orally Improving antioxidant defense system 
(↑CAT, GST,  GPx  and  GSH) and 










Intraperitoneally Reduces left ventricular (LV) posterior 
wall thickness and interventricular septum 
thickness. Anti-fibrosis effect through 
downregulation of ECM proteins 









Orally Reduced BP through components of the 
renin-angiotensin II system as well as 
reduction of cardiac hypertrophy via down 













Table 4: In vitro cardioprotective activity of GA with test model, concentration used, proposed 1 
mechanism of action 2 
Reported 
activity 







Cultured 3T3‐L1 cells 10 μM Stimulation of glucose uptake 
through translocation and 
activation of GLUT4 in Akt 
signaling pathway 
[57] 
Cultured rat pancreas 
homogenates 
20 μM Reduction of   MDA contents, 
improved ROS scavenging, Fe2+ 
chelation and Fe3+ reduction 
property of the cultured cells and 
inhibition of α-amylase and α-
glucosidase  
[35] 
Culturd RINm5F β‐cell 0.3–10 μM Significant increase insulin 
secretion and upregulation of  
mRNA of PDX-1 in cultured 
cells 
[58] 
In vitro insulin fibril 
formation 











stressed in cultured 
(H9c2(2-1))  cells 
10 μM Elevation of antioxidant defense 
mechanism (SOD, CAT, GSH) 
and scavenging ROS as well as 
reduction of LPO 
[104] 
AGE-treated in cultured  
H9c2(2-1) cell 
10 μM Attenuates upregulation of 
AGE-induced cytokines (TNF-α, 
TGF-β, iNOS and matrix 





100 μM Attenuation of cardiac fibrosis 
and reduced the expression of 
histone deacetylase 1 and 2   
[102] 
ISO treated cultured 
H9c2(2-1) cells  
100 μM Downregulation of ANP, BNP, 
and MHC-β as well as 
downregulation of JNK2 and 




H9c2(2-1)  cell 
100 μM Downregulation of GATA4-
induced Nox activity in 
















































1) Duplication of data 
& title.  
2) Non-relevance data. 
Scientific evidence from 
Databases  
(PubMed, Google Scholar, 
Web of science, Science 





Figure 3. Proposed anti-diabetic and cardioprotective mechanism of action of GA 2 
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